1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
The development of CagriSema represents a significant step towards more effective treatments for Type 2 Diabetes and obesity, conditions that often coexist and exacerbate each other. If the study demonstrates superior…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
This study is crucial as it investigates the effectiveness of low-dose semaglutide in a specific, underrepresented population: obese non-diabetic adults in Pakistan. If successful, the findings could support the broad…
The identification of predictive urinary biomarkers could revolutionize the management of Type 2 Diabetes by enabling truly personalized medicine. This approach could allow clinicians to select the most effective ther…
If successful, this novel approach could offer a significant advancement for patients with Type 2 Diabetes who are dependent on insulin. Reducing or eliminating the need for insulin injections would substantially impr…
Oral semaglutide represents a significant advancement in Type 2 Diabetes management, offering a convenient oral alternative to injectable GLP-1 receptor agonists. Real-world studies like this are vital because they pr…
If successful, this Phase 3 trial could introduce a new, potentially effective treatment option for Type 2 Diabetes patients who require additional glycemic control beyond oral medications. A positive outcome could le…
Obesity-related asthma represents a significant clinical challenge, often resistant to conventional treatments and associated with poorer outcomes. Semaglutide, by targeting obesity and potentially inflammation, offer…
This study is significant as it reinforces the global applicability and consistent safety profile of semaglutide for managing Type 2 Diabetes across diverse ethnic populations. Confirming its tolerability and safety i…
The potential for Semaglutide to cause delayed gastric emptying presents a substantial challenge for surgical planning and patient safety, particularly concerning anesthesia risks. If successful, this study could esta…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
The successful completion of SURMOUNT-CN is a crucial step towards expanding the availability of effective obesity treatments globally, specifically addressing the needs of the Chinese population. Tirzepatide, a dual …
Understanding the direct haemodynamic mechanisms of semaglutide and tirzepatide is crucial for optimizing their use in patients with cardiovascular diseases. This research could reveal novel pathways through which the…
This real-world SMILE study provides compelling evidence that semaglutide 2.4 mg delivers sustained and clinically meaningful cardiometabolic benefits beyond just weight loss in a diverse patient population. The obser…
This review significantly advances our understanding of the dermatological profile of GLP-1RAs, providing crucial insights for clinicians prescribing these medications. The identification of both common cutaneous adve…
This summary from an ICER council is crucial because it provides an independent, evidence-based assessment of the clinical and economic value of two highly effective anti-obesity medications. Such reviews are instrume…
This research is crucial for identifying cognitive-behavioral markers that predict successful long-term weight loss following bariatric surgery or liraglutide treatment. Understanding these markers could lead to more …
This case report highlights a critical safety concern, suggesting that clinicians should exercise extreme caution when reinitiating GLP-1 receptor agonists like semaglutide after a treatment break. The key implication…
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure…
This review suggests a paradigm shift in treating bile acid diarrhea, moving beyond traditional bile acid sequestrants to a more targeted physiological approach. The findings strongly support further investigation int…
This review highlights the significant potential of GLP-1 RAs as a superior therapeutic option for steroid-induced diabetes, moving beyond insulin-centric approaches. Their dual benefits of improving glycemic control …
This study identifies a new genetic cause for FPLD2, specifically the c.604G>C (p.Glu202Gln) variant in the LMNA gene, significantly expanding our understanding of its molecular basis. The discovery of novel pathogeni…
This study provides compelling preclinical evidence that semaglutide, a widely used GLP-1 receptor agonist for type 2 diabetes and obesity, possesses significant neuroprotective properties against chemotherapy-induced…
This RANDOMIZED, QUADRUPLE, TREATMENT trial is currently RECRUITING participants, with an estimated completion in December 2028, meaning no results are available yet. The study is meticulously designed to investigate …
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
If the results demonstrate significant efficacy and a favorable safety profile, Survodutide could represent a substantial advancement in the treatment landscape for obesity disease in Japan. This is particularly impor…
The findings from this trial, once fully published, could significantly impact clinical guidelines for managing Type 2 Diabetes in the critical post-hospitalization period. Identifying effective non-insulin options li…
While this specific trial did not yield results, the underlying research questions remain highly relevant for Type 1 Diabetes management. Effectively addressing hypoglycemia-induced oxidative stress, inflammation, and…
This foundational Phase 1 study was critical for advancing liraglutide into subsequent clinical development stages. By establishing a preliminary safety and pharmacokinetic profile in humans, it provided the necessary…
This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative h…
This study provides compelling evidence that Liraglutide offers superior benefits for endothelial function compared to Sitagliptin in patients with Type 2 Diabetes. This enhanced endothelial health could translate int…
Establishing bioequivalence is a critical regulatory step in drug development, especially when a drug's formulation changes between clinical trial phases. This ensures that the safety and efficacy data gathered in ear…
Consistent with the study's primary objective and anticipation, liraglutide demonstrated a significantly greater impact on body weight reduction compared to metformin. Participants receiving liraglutide achieved an av…
Prader-Willi Syndrome patients face profound challenges with hyperphagia and severe obesity, which significantly impact their health and quality of life. Liraglutide, with its established appetite-suppressive and weig…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
The potential for CagriSema to offer enhanced weight loss beyond current leading therapies like semaglutide represents a significant advancement in treating obesity. If successful, this combination could provide a mor…
Understanding semaglutide's direct neurological effects in healthy individuals is profoundly important for expanding its therapeutic potential. If this study reveals positive acute cognitive or energy-enhancing effect…
This real-world study is crucial for understanding how oral semaglutide performs outside of controlled clinical trials, providing valuable insights into its effectiveness and safety in a diverse patient population und…
While this real-world study involving 388 participants is completed, specific results are pending publication. However, based on extensive prior clinical trials, oral semaglutide is known to significantly improve glyc…